June saw EMA approval for phase III trials, successful drug production, and expanded U.S. clinical collaboration. Scientific advances were recognized in top journals and by international media, while regulatory and partnership milestones strengthened the clinical program.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.